IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Codexis and Merck Develop Prototype Enzyme-Based Method for Production of an Active Ingredient

12:31 AM MDT | April 4, 2012 | Deepti Ramesh

Codexis says that collaborative research by Merck & Co. (Whitehouse Station, NJ) and Codexis scientists to develop an enzyme-based production method for a key intermediate in the production of boceprevir has been recently published in the Journal of the American Chemical Society (JACS). Boceprevir is the active ingredient in Merck's Victrelis capsules for the treatment of chronic hepatitis C. Codexis is a developer of industrial enzymes to enable the production of biofuels, biobased chemicals and pharmaceutical intermediates. “The Codexis technology has...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa